Compare Danaher Corporation (DHR) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Procter & Gamble Co — how do they compare? Danaher Corporation trades at $198.81 (market cap $140.88B), while Procter & Gamble Co trades at $146.15 (market cap $340.16B). The key difference: Procter & Gamble Co is far larger — about 2.4× Danaher Corporation's market cap, and Procter & Gamble Co pays the higher dividend (2.92%). Which is the better fit depends on your goals.
| DHR | PG | |
|---|---|---|
Market Cap | $140.88B | $340.16B |
Sector | Health | Consumer Staples |
52-Week High | $242.05 | $167.18 |
52-Week Low | $161.91 | $138.10 |
Enterprise Value | $153.66B | $365.64B |
Dividend Yield | 0.8% | 2.92% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
Procter & Gamble (PG) trades at $148.37, up 0.9% with a neutral technical outlook. The company maintains strong fundamentals with $84.28B revenue and 19.16% net income margin, consistently beating earnings estimates. Recent dividend declaration of $1.09 and WNBA partnership highlight stable returns and brand expansion. Analyst consensus is bullish with 53.85% buy ratings and $161.71 price target, though premium valuation metrics suggest cautious optimism.
PG offers steady growth with reliable dividends but faces margin pressure from rising costs. The stock's premium valuation requires sustained earnings growth to justify upside. Near-term resistance at $150 presents a key level to watch, while support at $145 provides downside protection. Institutional activity remains mixed amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
